These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23762372)

  • 1. Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.
    Bieńkowski M; Piaskowski S; Stoczyńska-Fidelus E; Szybka M; Banaszczyk M; Witusik-Perkowska M; Jesień-Lewandowicz E; Jaskólski DJ; Radomiak-Załuska A; Jesionek-Kupnicka D; Sikorska B; Papierz W; Rieske P; Liberski PP
    PLoS One; 2013; 8(6):e65444. PubMed ID: 23762372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-dependent prognostic effects of genetic alterations in glioblastoma.
    Batchelor TT; Betensky RA; Esposito JM; Pham LD; Dorfman MV; Piscatelli N; Jhung S; Rhee D; Louis DN
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):228-33. PubMed ID: 14734474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
    McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
    Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analyses for predictors of radiation response in glioblastoma.
    Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.
    Koshiyama DB; Trevisan P; Graziadio C; Rosa RFM; Cunegatto B; Scholl J; Provenzi VO; de Sá AP; Soares FP; Velho MC; de A P Filho N; Oliveira CA; Zen PRG
    J Neurooncol; 2017 Dec; 135(3):465-472. PubMed ID: 28856550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of molecular biomarkers in glioblastoma.
    Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
    Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients.
    Zhao HF; Zhou XM; Wang J; Chen FF; Wu CP; Diao PY; Cai LR; Chen L; Xu YW; Liu J; Li ZY; Liu WL; Chen ZP; Huang GD; Li WP
    J Transl Med; 2021 Aug; 19(1):372. PubMed ID: 34461927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme.
    Lopez-Gines C; Cerda-Nicolas M; Gil-Benso R; Pellin A; Lopez-Guerrero JA; Callaghan R; Benito R; Roldan P; Piquer J; Llacer J; Barbera J
    Clin Neuropathol; 2005; 24(5):209-18. PubMed ID: 16167544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
    Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
    JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    Wilcock DM; Goold E; Zuromski LM; Davidson C; Mao Q; Sirohi D
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):338-344. PubMed ID: 38605523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
    Armocida D; Pesce A; Frati A; Santoro A; Salvati M
    J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
    Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
    Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.